The analysis of the functioning of the pharmaceutical market of Ukraine in the context of implementing ethical codes and self-regulatory mechanisms for promotional activities
DOI:
https://doi.org/10.24959/sphhcj.25.374Abstract
In the context of increasing competition in the pharmaceutical market of Ukraine and the growth of marketing investments, there is an urgent need to revise the legislative regulation of the drug promotion and to introduce professional self‑regulatory mechanisms aimed at preventing unethical practices, conflicts of interest, and enhancing trust in the healthcare system.
Aim. To analyze the specific features of the functioning of the pharmaceutical market of Ukraine with an assessment of the coverage of its key stakeholders by ethical codes and industry self‑regulatory mechanisms of the drug promotion.
Materials and methods. The study was based on data from scientific literature, media sources (Apteka Weekly, ThePharma.Media, FiercePharma), international and national regulatory acts and ethical codes, publicly available financial statements of pharmaceutical companies for 2023–2024, as well as data from the PharmXplorer analytical system for 2020 – the first half of 2025. The content analysis, comparative legal analysis, structural and logical analysis, and descriptive statistical methods with tabular and graphical presentation of results were applied.
Results and discussion. The analysis of the dynamics of the number of manufacturers and marketing authorization holders operating in the pharmaceutical market of Ukraine during 2020–2024 showed that the share of domestic manufacturers remained stable (10–11 %), while the share of domestic marketing organizations increased from 36 % to 38 %. In 2024, Ukraine accounted for the largest individual share of retail sales by both country of manufacture (37 %) and country of the marketing organization (42 %), while foreign companies continued to dominate the total retail sales of medicinal products. Among foreign drug manufacturers, companies from Germany (16.4 %), India (11.4 %), Italy (9.6 %), and France (9.5 %) prevailed. Among international marketing organizations, India (15.3 %), Germany (14.4 %), and the United Kingdom (8.7 %) held leading positions in terms of the number of companies. It was found that in 2024, Germany had the largest share in the structure of retail sales by both country of manufacture and country of the marketing organization among major foreign companies (13 % and 11 %, respectively). It was found that only about 10–11 % of marketing organizations were formally covered by industry ethical codes; however, these organizations account for nearly 44 % of the retail pharmaceutical market. The analysis of financial statements revealed a substantial share of marketing expenditures in the sales cost structure of leading domestic companies, reaching 57.8–77.4 % in 2024.
Conclusions. The results obtained indicate an uneven development of ethical self‑regulatory mechanisms in the pharmaceutical market of Ukraine and their limited quantitative coverage despite high economic concentration. This substantiates the need to expand industry self‑regulation practices among national manufacturers and marketing organizations and harmonize the national regulation of the drug promotion with international ethical standards, taking into account the market structure and the concentration of marketing expenditures.
References
Mulinari, S., Martinon, L., Jachiet, P. A., & Ozieranski, P. (2021). Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries. Health policy (Amsterdam, Netherlands), 125(7), 915–922. https://doi.org/10.1016/j.healthpol.2021.04.015
Ozieranski, P., Martinon, L., Jachiet, P. A., & Mulinari, S. (2022). Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe. International journal of health policy and management, 11(12), 2842–2859. https://doi.org/10.34172/ijhpm.2022.6575
Ozieranski, P., Martinon, L., Jachiet, P. A., & Mulinari, S. (2021). Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review. BMJ open, 11(12), e053138. https://doi.org/10.1136/bmjopen-2021-053138
Ozieranski, P., Saito, H., Rickard, E., Mulinari, S., & Ozaki, A. (2023). International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Globalization and health, 19(1), 14. https://doi.org/10.1186/s12992-022-00902-9
International Federation of Pharmaceutical Manufacturers Associations. (2019). IFPMA code of practice. https://www.ifpma.org/publications/ifpma-code-of-practice
European Federation of Pharmaceutical Industries and Associations. (2024). EFPIA code of practice (Consolidated version 2024). https://www.efpia.eu/media/636989/efpia-code-of-practice.pdf
Promotion ethics: AIPM Ukraine code of conduct. (n. d.). AIPM Ukraine. https://aipm.org.ua/en/promotion-ethics
Kotvitska, A. A., Surikova, I. O., & Havrysh, N. B. (2015). Doslidzhennia vprovadzhennia etychnoho kodeksu farmatsevtychnykh pratsivnykiv Ukrainy u praktychnu diialnist. Sotsialna farmatsiia v okhoroni zdorovia, 1(1), 45–52. https://doi.org/10.24959/sphhcj.15.7
Olkhovska, A. B., & Malyi, V. V. (2018). Naukovo-teoretychne obgruntuvannia napriamiv rozvytku marketynhovoi komunikatyvnoi diialnosti subiektiv farmatsevtychnoho rynku v konteksti kontseptsii sotsialno-etychnoho prosuvannia. Sotsialna farmatsiia v okhoroni zdorovia, 4(4), 66–75. https://doi.org/10.24959/sphhcj.18.130
Pestun, I. V., & Mnushko, Z. M. (2020). Vplyv normatyvno-pravovoho rehuliuvannia na marketynhovu diialnist optovo-rozdribnykh farmatsevtychnykh orhanizatsii. Sotsialna farmatsiia v okhoroni zdorovia, 6(3), 49–59. https://doi.org/10.24959/sphhcj.20.191
Tolochko, V. M., Zarichkova, M. V., Surikov, O. O., Kurhan, A. V., & Khmelnytska, O. A. (2020). Doslidzhennia stavlennia spetsialistiv farmatsii do telereklamy likarskykh zasobiv. Sotsialna farmatsiia v okhoroni zdorovia, 6(3), 18–25. https://doi.org/10.24959/sphhcj.20.196
Boldar, H. Ye., Korzh, Yu. V., Tereshchenko, L. V., & Afanasenko, O. V. (2024). Analiz pravovoho rehuliuvannia ta suchasnykh prykladnykh aspektiv sotsialnoi reklamy v okhoroni zdorovia. Sotsialna farmatsiia v okhoroni zdorovia, 10(4), 19–31. https://doi.org/10.24959/sphhcj.24.338
Farmkompanii pochaly vytrachaty levovu chastku reklamnoho biudzhetu na “tsyfru”. ThePharma.Media. https://thepharma.media/uk/news/31608-farmkompanii-nacali-tratit-lvinuyu-dolyu-reklamnogo-byudzeta-na-cifru-28022023
Marketynhovi platezhi - plata za mistse na polytsi, a ne instrument znyzhennia tsiny dlia spozhyvacha. ThePharma.Media. https://thepharma.media/uk/news/38507-marketingovi-platezi-plata-za-misce-na-polici-a-ne-instrument-znizennya-cini-dlya-spozivaca-30052025
Aptechnyi prodazh za pidsumkamy I pivrichchia 2025 r. Shchotyzhnevyk Apteka. https://www.apteka.ua/article/728144
Aptechnyi prodazh za pidsumkamy 2024 r. Shchotyzhnevyk Apteka. https://www.apteka.ua/article/712849
Aptechnyi prodazh za pidsumkamy 2023 r. Shchotyzhnevyk Apteka. https://www.apteka.ua/article/684747
Aptechnyi prodazh za pidsumkamy 2022 r. Shchotyzhnevyk Apteka. https://www.apteka.ua/article/656982
Top 20 pharma companies by 2024 revenue. Fierce Pharma. https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2024-revenue
Ethical criteria for medicinal drug promotion (1988). World Health Organization. https://iris.who.int/handle/10665/164501
Zakon Ukrainy “Pro reklamu” No. 270/96-VR (1996, Lypen 03). Vidomosti Verkhovnoi Rady Ukrainy. https://zakon.rada.gov.ua/laws/show/270/96-%D0%B2%D1%80
Nakaz MOZ Ukrainy “Pro deiaki pytannia reklamy likarskykh zasobiv” No. 422 (2012, Cherven 06). Vidomosti Verkhovnoi Rady Ukrainy. https://zakon.rada.gov.ua/laws/show/z1189-12
Nakaz MOZ Ukrainy “Pro zatverdzhennia Pereliku likarskykh zasobiv, zaboronenykh do reklamuvannia, yaki vidpuskaiutsia bez retsepta” No. 457. (2024, Berezen 18). Vidomosti Verkhovnoi Rady Ukrainy. https://zakon.rada.gov.ua/laws/show/z0476-24
Members. (n. d.). AIPM Ukraine. https://aipm.org.ua/en/members
Nazvy kompanii ta adresy (perelik chleniv APRAD). (n. d.). Asotsiatsiia vyrobnykiv innovatsiinykh likiv “APRAD”. https://aprad.org.ua/category/nazvi-kompaniy-ta-adresi
APRAD code of ethics. (2020). Association of Pharmaceutical Research and Development. https://aprad.org.ua/en/innovatsiyna-farma/etichniy-kodeks/
Etychnyi kodeks likaria Ukrainy. (2009, Veresen 27). https://zakon.rada.gov.ua/go/n0001748-09
Etychnyi kodeks farmatsevtychnykh pratsivnykiv Ukrainy (zatverdzheno 15-17.09.2010). Shchotyzhnevyk Apteka. https://www.apteka.ua/article/126803
The Blue Book: Pfizer code of conduct. (2025). Pfizer. https://www.pfizer.com/about/responsibility/code-of-conduct
Novartis code of ethics. (2020). Novartis. https://www.novartis.com/about/our-company/corporate-governance/novartis-code-ethics
Roche Group code of conduct (Including reference to the Roche Pharma Directive on interactions with health care professionals and healthcare organizations). (2024). Roche. https://www.roche.com/sustainability/ethics-integrity/code-of-conduct
Richnyi zvit za 2024 rik. (2024). PrAT Farmatsevtychna firma “Darnytsia”. https://admin.darnytsia.ua/sites/default/files/2025-10/richniy-zvit-2024.zip
AT “Farmak”. Okrema finansova zvitnist za rik, yakyi zakinchyvsia 31 hrudnia 2024 roku. https://farmak.ua/wp-content/uploads/2025/09/okrema-finansova-zvitnist-za-rik-yakij-zakinchivsya-31-grudnya-2024-roku.pdf
PrAT “Kyivskyi vitaminnyi zavod”. Finansova zvitnist zghidno MSFZ za rik, shcho zakinchyvsia 31 hrudnia 2024 roku. https://www.vitamin.com.ua/wp-content/uploads/2025/05/finansova-zvitnist-zghidno-msfz-za-2024-rik.pdf
Asotsiatsiia “Vyrobnyky likiv Ukrainy”. https://avlu.org.ua/
Yaki novi vymohy do reklamy likarskykh zasobiv zaprovadzhuiutsia u zhovtni? Shchotyzhnevyk Apteka. https://www.apteka.ua/article/676119
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
